Peran Toksin Botulinum Tipe A (BoNT-A) pada Spastisitas Pasien Cerebral Palsy
DOI:
https://doi.org/10.55175/cdk.v46i4.484Keywords:
Cerebral palsy, spastisitas, toksin BotulinumAbstract
Cerebral palsy (CP) merupakan sindrom klinis berupa gangguan postur dan gerakan yang menetap karena gangguan non-progresif pada perkembangan otak imatur. Spastisitas merupakan subtipe CP berdasarkan abnormalitas motorik yang paling banyak ditemukan. Salah satu pendekatan untuk menangani spastisitas tersebut adalah dengan injeksi Toksin Botulinum tipe A (BoNT-A). BoNT-A dapat dikatakan aman, keberhasilannya tergantung pada banyak faktor.
Cerebral palsy (CP) is a clinical syndrome which involves permanent posture and movement disorders due to non-progressive disorder in immature brain development. Spasticity is the most common subtypes of CP based on motor abnormalities, resulting in limitation of activities. Botulinum Toxin type A (BoNT-A) injections is safe, but the success depends on many factors.
Downloads
References
Novak I, Morgan C, Adde L, Blackman J, Boyd RN, Brunstrom-Hernandez J, et al. Early, accurate diagnosis and early intervention in cerebral palsy: Advances in diagnosis and treatment. JAMA Pediatr. 2017;171(9):897–907
Shamsoddini A, Amirsalari S, Hollisaz MT, Rahimnia A, Khatibi-Aghda A. Management of spasticity in children with cerebral palsy. Iran J Pediatr. 2014;24(4):345-51
Pavone V, Testa G, Restivo DA, Cannavo L, Condorelli G, Portinaro NM, et al. Botolinum toxin treatment for limb spasticity in childhood cerebral palsy. Front Pharmacol. 2016;7:29
Copeland L, Edwards P, Thorley M, Donaghey S, Gascoigne-Pees L, Kentish M, et al. Botulinum toxin A for nonambulatory children with cerebral palsy: A double blind randomized controlled trial. J Pediatr. 2014;165(1):140-6
Gunawan PI, Saharso D. Reducing severe spasticity in cerebral pals following meningoencephalitis by botulinum toxin. Med J Indones. 2017;26:76-80
Strobl W, Theologis T, Brunner R, Kocer S, Viehweger E, Pascual-Pascual I, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins. 2015;7:1629-2648
Sitorus FSAB, Mogi TI, Gessal J. Prevalensi anak cerebral palsy di instalasi rehabilitasi medik RSUP Prof. DR. R. D. Kandou Manado periode 2015. JKK. 2016;1(1):14-9
Moeini-Naghani I, Hashemi-Zonouz T, Jabbari B. Botulinum toxin treatment of spasticity in adults and children. Semin Neurol. 2016;36:64-72
Molenaers G, Fagard K, Campenhout A, Desloovere K. Botulinum toxin A treatment of the lower extremities in children with cerebral palsy. J Child Orthop. 2013;7:383-7
Kahraman A, Seyhan K, Deger U, Kutluturk S, Mutlu A. Should botulinum toxin A injections be repeated in children with cerebral palsy? A systematic review. Dev Med Child Neurol. 2016;58(9):910-7
Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A [Xeomin® ] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. Eur J Pediatr Neurol. 2016;20(4):532-7
Lidmann G, Nachemson A, Peny-Dahlstrand M, Himmelmann K. Botulinum toxin A injections and occupational therapy in children with unilateral spastic cerebral palsy: A randomized controlled trial. Dev Med Child Neurol. 2015;57(8):754-61
Heest AE, Bagley A, Molitor F, James MA. Tendon transfer surgery in upper-extremity cerebral palsy is more effective than botulinum toxin injections or regular, ongoing therapy. J Bone Joint Surg Am. 2015;97:529-36
Ulici A, Sterian AG, Tevanov I, Popescu MB. Use and adverse effects of botulinum toxin in management of children with spastic cerebral palsy. Farmacia. 2017;65(3):454-9
Papavasiliou AS, Nikaina I, Foska K, Bouros P, Mitsou G, Filiopoulos C. Safety of botulinum toxin A in children and adolescents with cerebral palsy in pragmatic setting. Toxins. 2013;5:524-36
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
